Q-Immune, Inc. — SEC Form D Filing

Q-Immune, Inc. filed an SEC Form D on September 28, 2026, reporting $25K raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
September 28, 2026
Amount reported
$25K
Round stage
Seed
Industry
Biotechnology
Website
https://www.qimmune.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: WASHINGTON

Problem

Biology is dynamic, yet traditional data is static, leading to unpredictable consequences even from small changes in cellular systems. This makes programming safety into cell therapies for complex diseases a significant challenge.

Solution

QMI is a technology that reads what a cell does to generate data for modeling and predicting cellular behavior. This allows Q-Immune to design and measure cellular activity, test real outcomes, and learn patterns to program safety into cell therapies for oncology, autoimmune, and neuroscience conditions.

Why now

Advances in cell therapy and gene editing have opened new possibilities for treating complex diseases, but also increased the need for robust methods to ensure the safety and predictability of these highly complex biological interventions.

Verdict

Investors funded this seed round betting on the emergent need for predictive safety and efficacy modeling in advanced cell therapies, specifically addressing the unpredictability inherent in dynamic biological systems. This cleared because of the compelling *vision* of programmed safety for high-stakes treatments, not because the underlying technology was fully validated or demonstrated broad applicability beyond initial proof-of-concept. The limited upside at this stage was tied to the very early nature of the core technology, which remained largely conceptual and undemonstrated in its commercial form, presenting significant technical and regulatory hurdles.

Source: SEC EDGAR Form D filing